|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on November 27, 2002; DOI 10.1182/blood-2002-10-3091.
NEOPLASIA
From the Division of Oncology, Departments of Medicine
and Pathology, Stanford University, CA; Reproductive Genetics Unit,
Department of Obstetrics, Gynecology and Reproductive Sciences,
University of California, San Francisco; and the Department of Cellular
and Molecular Biology The targeted inactivation of oncogenes may be a specific and
effective treatment for cancer. However, because human cancers are the
consequence of multiple genetic changes, the inactivation of one
oncogene may not be sufficient to cause sustained tumor regression.
Moreover, cancers are genomically unstable and may readily compensate
for the inactivation of a single oncogene. Here we confirm by spectral
karyotypic analysis that MYC-induced hematopoietic tumors
are highly genetically complex and genomically unstable.
Nevertheless, the inactivation of MYC alone was found to be
sufficient to induce sustained tumor regression. After prolonged MYC inactivation, some tumors exhibited a distinct
propensity to relapse. When tumors relapsed, they no longer required
the overexpression of MYC but instead acquired novel
chromosomal translocations. We conclude that even highly genetically
complex cancers are reversible on the inactivation of MYC,
unless they acquire novel genetic alterations that can sustain a
neoplastic phenotype.
(Blood. 2003;101:2797-2803) Tumorigenesis is associated with the activation of
oncogenes and the inactivation of tumor-suppressor genes.1
The pharmacologic inactivation of these mutant genes may be an
effective therapy for cancer. Human cancer cells generally possess many
genetic abnormalities, so that the repair or inactivation of a single mutant gene may not be sufficient to induce sustained tumor regression. Moreover, because cancers are genomically unstable, they may readily acquire genetic lesions that could compensate for any pharmacologically inactivated gene product.
The MYC proto-oncogene may be a good pharmacologic target
for the treatment of human cancer. MYC has been implicated
in the pathogenesis of many types of human neoplasia, in particular
hematopoietic tumors such as Burkitt lymphoma, large B-cell lymphoma,
lymphoblastic lymphoma, and multiple myeloma.2-4 A
consistent feature of these tumors is that MYC expression
levels are up-regulated through several different mechanisms, including
chromosomal translocation, genomic amplification, and
mutation.2,4,5 MYC normally regulates cellular
growth and proliferation and, under some circumstances, induces
apoptosis. MYC overexpression is thought to contribute to
tumorigenesis by causing unrestrained cellular proliferation, blocking
differentiation, and perhaps promoting genomic
destabilization.2
Many oncogenes are known to cooperate with MYC during
tumorigenesis, including Ras,6
Bcl-2,7
Bmi-1,8Pim-1,9 and Pim-2.10 Similarly, the loss of function of
many tumor-suppressor genes, including p53 and
p19ARF, has been shown to cooperate with MYC to
induce tumorigenesis.11 Hence, MYC is thought
to induce tumorigenesis in concert with multiple genetic factors.
More recently, chromosomal aberrations in tumors associated
with MYC overexpression have been identified by spectral
karyotypic analysis (SKY). SKY is a multicolor chromosome painting
method that allows for visualization of chromosomal abnormalities
otherwise difficult to identify in mouse metaphases.12
Examples of abnormalities detected using SKY include translocations in
myeloma,13 chromosomal alterations in mammary
tumors,14 and recurrent translocations in
MYC-induced BALB/c plasmacytomas.15
To determine whether MYC may be an effective target for
cancer therapy, we developed a conditional transgenic model system for
the regulation of MYC expression in murine hematopoietic
tumors.16 We reported that with MYC
inactivation, hematopoietic tumors undergo sustained regression. After
prolonged MYC inactivation, we found that 20% of the tumors
relapsed, apparently bypassing the requirement for continued
MYC overexpression. We concluded that MYC-induced hematopoietic tumorigenesis is reversible, but that there are mechanisms by which tumors can become independent of MYC. We
postulated that there might be genetic changes that can functionally
replace the requirement of MYC overexpression to sustain a
neoplastic phenotype.
Here we have characterized the ability of individual
MYC-induced tumors to undergo sustained regression upon
MYC inactivation. We found that individual tumors exhibit a
distinct propensity to relapse with prolonged MYC
inactivation and that when tumors relapse, they become independent of
MYC to maintain their neoplastic features. Moreover, through
the use of SKY, we examined a panel of primary MYC-induced
hematopoietic tumors and variants of these tumors that had relapsed
after prolonged MYC inactivation. We found that primary
transgenic tumors exhibited complex patterns of karyotypic
abnormalities, including aneuploidy, polyploidy, homogeneously stained
regions (HSRs), and chromosomal translocations. Relapsed tumor variants
consistently acquired novel chromosomal translocations. Our results
confirm that MYC inactivation is sufficient to induce
sustained tumor regression even in genomically complex tumors, and they
suggest that there may be genetic changes that can functionally
compensate for the requirement of MYC overexpression to
maintain a neoplastic phenotype.
Tumor cell lines and tumorigenicity assays
Western blots
Metaphase preparation and spectral karyotypic analysis Metaphase spreads were prepared according to standard procedures. Briefly, 1 mg/mL colcemide was added to the cells for 30 minutes in early passage. Cells were incubated with 0.075 M KCl for 20 minutes and then were fixed using methanol/acetic acid fixative. Spectral karyotyping was performed using the Applied Spectral Imaging (ASI; Carlsbad, CA) skypaint kit for mouse chromosomes, according to the manufacturer's protocol. SKY images were acquired with a Spectracube-2 (ASI) mounted on a Leica DMR microscope. Acquisition and analysis were performed using the ASI image capturing (SI 2.2) and analysis software (SkyView 1.6.1). At least 15 metaphase spreads of good spectral hybridization quality and banding morphology were analyzed for each preparation. Every karyotype was confirmed by cytogenetic G-banding analysis.
Tumor regression and relapse upon MYC inactivation Previously, we described the use of the tetracycline regulatory system to generate transgenic mice that conditionally overexpress the MYC proto-oncogene in hematopoietic cells.16 In this system, the tetracycline-transactivating protein (tTA) mediates the transcription of MYC placed under the control of the tetracycline-responsive promoter (tet-o). The presence of doxycycline inactivates the transcription mediated by tTA, and MYC is turned off. In the absence of doxycycline, mice develop hematopoietic tumors. When treated with doxycycline, 100% of the tumors initially regressed and 80% of the tumors showed sustained tumor regression with continuous doxycycline treatment. Approximately 20% of the tumors relapsed after prolonged MYC inactivation. We concluded that MYC-induced tumorigenesis is reversible but that some tumors can become independent of MYC for their neoplastic properties.We considered there are 2 possible explanations for the relapse of some tumors after prolonged MYC inactivation. First, all tumors may have the ability to give rise to rare cells that have acquired the ability to become independent of MYC for their neoplastic properties. Second, only some of the tumors may have an inherent ability to relapse following prolonged MYC inactivation. To distinguish between these 2 possibilities, we generated a panel of tumor-derived cell lines. We reasoned that if the ability of a tumor to relapse after MYC inactivation is a property of all tumors, then each tumor should exhibit a similar ability to relapse. Previously, we verified that tumor-derived cell lines faithfully continue to exhibit a conditional malignant phenotype in vitro and in vivo.16 We confirmed that each of these cell lines had lost its neoplastic features upon MYC inactivation in vitro, as demonstrated by the loss of cellular proliferation and the induction of apoptosis, observed by phase microscopy, trypan blue staining, and fluorescence-activated cell sorter (FACS) analysis for DNA content (data not shown). These results are similar to what we described previously in detail.16 To directly investigate the ability of each tumor to relapse after
MYC inactivation, we inoculated 12 primary tumor lines into
at least 10 syngeneic mice. When mice were moribund with tumor burden,
we investigated the ability of tumors to regress on the inactivation of
MYC (Table 1, Figure 1).
Representative mice were killed and analyzed
grossly and histologically for evidence of tumors before and after MYC inactivation (Figure 1A-C).
Initially, tumors invaded and effaced the healthy architecture of the
thymus, spleen, and lymph nodes (Figure 1A). After MYC
inactivation, all tumors initially regressed; this was associated with
the restoration of healthy hematopoietic architecture (Figure 1B). Mice
were observed to determine the frequency at which tumors relapsed after
prolonged MYC inactivation. Some tumors consistently
relapsed after prolonged MYC inactivation (Figure 1C). In
summary, tumors behaved in 1 of 3 different manners. Many tumors
exhibited sustained tumor regression and were not observed to relapse
despite prolonged MYC inactivation (mouse nos. 1137, 1979, 2263, 5719, 5720). Other tumors relapsed in 10% to 50% of the mice
(mouse nos. 6780, 6021, 1232, 966, 967), and some tumors relapsed in
100% of the mice (mouse nos. 6814, 6816) after prolonged
MYC inactivation (Table 1, Figure
2). It was only from the same tumors that
had relapsed in vivo that we could isolate tumor cells that were able
to continue to proliferate in vitro after 2 to 8 weeks of doxycycline
treatment (Table 1). We conclude that although all
MYC-induced tumors initially regress upon MYC
inactivation, some tumors have the intrinsic ability to relapse and
become independent of MYC.
Relapsed tumors escape dependence on MYC overexpression We considered that there were 2 likely explanations for tumor relapse after prolonged MYC inactivation. First, tumors may find a means to restore MYC overexpression through bypassing the tetracycline regulatory system or activating the expression of endogenous Myc. Second, tumors may acquire novel genetic alterations that can functionally replace the ability of MYC to maintain a tumorigenic phenotype. To address the first possibility, we examined the protein expression of transgenic human c-MYC and endogenous mouse c-, N-, and L-Myc proteins in primary tumors and in tumors that had relapsed after doxycycline treatment. We used antibodies specific for human c-MYC (9E10) for human and mouse c-Myc (c19) or mouse N-Myc (OP13) and L-Myc (c20) (Figure 3). As expected, we found that primary tumors expressed the MYC protein in the absence of doxycycline but failed to exhibit expression of the human MYC transgene in the presence of doxycycline (Figure 3). Furthermore, we found that relapsed tumors similarly did not express the MYC transgene in the presence of doxycycline treatment. Some of the primary tumors and relapsed tumors exhibited low levels of expression of endogenous c-Myc, but all failed to express N- or L-Myc in the presence of doxycycline treatment. Note that because c-Myc is located on chromosome (Chr) 15, the small relative increase of c-Myc seen in some of the primary and relapsed tumors could be related to the gain of Chr 15 (see below). However, none of the relapsed tumors exhibited levels of c-Myc higher than those detected in the primary tumors. We conclude that relapsed tumors became independent of MYC overexpression for the maintenance of their tumorigenic properties.
Primary tumors exhibit complex and unique patterns of genomic changes We considered that the propensity of individual tumors to relapse might reflect the particular combination of genomic alterations in a given tumor. To characterize the patterns of genomic alterations in primary and relapsed transgenic tumors, we performed cytogenetic analysis by inverted DAPI banding and SKY (summarized in Table 2). Representative SKY results and examples of the karyotypic abnormalities are shown in Figures 4 and 5. In the 16 primary tumors analyzed, clonal chromosomal abnormalities were identified in 14 (88%) cases. In 12 (75%) tumors, we noted numerical chromosomal aberrations. The most common numerical aberrations were gain of Chr 15 in 7 (44%) cases, gain of the Y chromosome in 4 (25%) cases, trisomy 4 or 11 in 5 (31%) cases, and trisomy 11 together with trisomy 15 in 3 (19%) cases. Loss of chromosomes occurred less frequently. The most common of these was the loss of the X chromosome in 2 (13%) cases.
In addition to the numerical changes, we noted that 4 (25%) tumors exhibited structural aberrations in chromosomes. We observed a nonbalanced translocation involving Chr 3 in 3 (19%) tumors, with the translocation partner originating from different chromosomes in different tumors. One tumor (6816) showed a translocation of Chr Y (t(Y;15)). Notably, only 2 (1936 and 1937) of the 16 (12%) primary tumors had no clonal structural or numerical chromosomal rearrangements, but they had several nonclonal alterations in individual metaphase cells. Tumor 1936 had numerical changes in 3 of 15 metaphases, whereas tumor 1937 exhibited numerical aberrations in 7 of 15 metaphases. The numerical changes observed were all random gains and losses of different chromosomes. Hence, the MYC-induced tumors contain complex unique patterns of genomic abnormalities and evidence for genomic destabilization. Our results underscore that genomically complex and unstable tumors can regress on the inactivation of a single oncogene. We attempted to identify genomic events that correlated with the
propensity of tumors to relapse. We were unable to correlate the
specific genomic abnormalities we observed with the ability of tumors
to relapse after MYC inactivation (Figure
6A). There are several possible
explanations. The sample size was likely too small to have enabled
discernment of the patterns of gross chromosomal changes associated
with a propensity to relapse. Alternatively, the genetic events
responsible might not have been detectable by karyotypic analysis, or a
nongenetic mechanism might have been responsible.
Relapsed tumors exhibit novel chromosomal translocations We noted that all the relapsed tumors exhibited additional chromosomal alterations when compared with their parent primary tumor (Table 2; Figures 4 and 6B). Structural chromosomal abnormalities were observed in 10 (91%) of the relapsed tumors. The most common abnormality was a nonreciprocal translocation involving Chr 3 (6 cases) (Figure 4), with the translocation partner varying between different tumors. In one case part of Chr 1, t(3;1)(H4;?), and in 2 cases part of chromosome 4, t(3;4)(H4;?), had translocated to the distal end of Chr 3, with the breakpoint at 3(H4). The translocation was always accompanied by an amplification of the distal part of Chr 3. An entire Chr 17 had translocated to a partial Chr 3 [+der(3)t(3;17)(G;A-D)] in 2 cases, and Chr 10 had translocated to a partial Chr 3 [+der(3)t(3;10)(G;A-D)] in one case. Two (18%) tumors showed an unbalanced translocation of Chr 1 and 18 [+der(1)t(1;18)(G;A-D)]. Therefore, the ability of a relapsed tumor to become independent of MYC to maintain its neoplastic properties correlated with the acquisition of a novel chromosomal translocation.Relapsed tumors also exhibited aneuploidy. The gain of Chr 15 in 8 (73%) cases was the most common numerical aberration. Trisomy 15 was the sole aberration in 1 case. Gain of the Y chromosome occurred in 3 (27%) cases (Table 2). Gain of Chr 4 or 11 was found in 5 (45%) cases, and trisomy 11 was observed with trisomy 15 in all those cases. Partial trisomy of Chr 3 was present in 5 (45%) tumors and was always associated with a translocation involving this chromosome. However, no specific chromosome was found to be consistently lost in the relapsed tumors. Thus, every relapsed tumor exhibited additional chromosomal rearrangements, both numerical and structural, compared with the primary tumor of origin (Figures 5-6). In 9 of 10 of the relapsed tumors, this structural rearrangement was a previously unidentified translocation. For 2 of the primary tumors (1232, 967), we analyzed 2 independently derived relapsed tumor variants. In both cases, the relapsed tumors originating from the same primary tumor exhibited different chromosomal abnormalities. Tumor 967 R1 contained an amplification of Chr 11, whereas tumor 967 R2 displayed a translocation of Chr 3 and an isochromosome (iso) 4. Tumor 1232 R3 had acquired an additional translocation of Chr 3 compared with tumor 1232 R2 (Table 1, Figure 5). We infer that even in a given primary tumor, more than one genetic event can functionally replace the ability of MYC to maintain tumorigenesis.
Many reports document that oncogene-induced tumorigenesis is reversible.16-22 Even brief oncogene inactivation can be sufficient to result in sustained tumor regression.20 Less clear is whether human tumors, which are generally presumed to be more genetically complicated than tumors arising in transgenic mice, would similarly regress with the inactivation of a single oncogene. Further complicating this issue is the recent suggestion that MYC can induce tumorigenesis in transgenic mice without associated genomic instability.21,23 On the contrary, we found that MYC-induced hematopoietic tumors are highly genetically complex and genomically unstable. Nevertheless, the inactivation of MYC alone was sufficient to induce sustained tumor regression. Moreover, each hematopoietic tumor exhibited different complex patterns of chromosomal aberration, suggesting that regardless of the combination of genomic disturbances, tumorigenesis induced by MYC overexpression is reversible with MYC inactivation. We infer from these results that it is likely that even in human tumors the inactivation of individual oncogenes may be effective in inducing sustained tumor regression. Collectively, our results raise 3 questions. First, why does inactivation of a single oncogene in a cancer that consists of multiple genomic abnormalities induce tumor regression? Second, can we predict when tumors will escape dependence on a given oncogene? Third, what are the mechanisms by which tumors become independent of a given oncogene? To address the first question, we consider there are at least 3 nonmutually exclusive explanations for why oncogene inactivation could cause tumor regression in genetically complex tumors. First, oncogene inactivation can restore the physiologic program of differentiation,16,20 and in this context genetic alterations could be silenced. We have recently shown that by even briefly inactivating MYC, we can induce the differentiation of tumor cells. In this new epigenetic context, the reactivation of MYC fails to restore the neoplastic features.20 Second, sustained oncogene activity may be required to provide for host factors for sustained growth, such as angiogenesis.17,21 Although this appears to be true under at least some circumstances, this would not appear to account for our observation that oncogene inactivation can cause the loss of a neoplastic phenotype in vitro.16,20 Third, oncogene inactivation may restore the function of endogenous DNA damage checkpoint mechanisms that initiate senescence or apoptotic programs. Previously, we proposed that MYC could abrogate the ability of healthy cells to appropriately respond to DNA damage.24 The inactivation of MYC may restore this function in tumor cells. Perhaps this would permit tumor cells to recognize that they are genomically damaged, resulting in the induction of differentiation, apoptosis, or both. We suspect that the specific mechanisms by which oncogene inactivation induces tumor regression are likely to be influenced by the particular oncogene involved, the combination of genetic events in a given tumor, and the specific type of cancer. Although MYC inactivation was sufficient to induce tumor regression, we found that tumors occasionally relapse. The tendency of a given hematopoietic tumor to relapse appears to be distinct for each tumor. Some tumors never or rarely relapse, whereas some tumors always relapse after prolonged MYC inactivation. Tumor relapse was associated with the loss of expression of the MYC transgene, without evidence that tumors activated the expression of endogenous Myc genes. We conclude that tumors can acquire the ability to recover their neoplastic properties independent of the expression of even the oncogene that initiated tumorigenesis. Our results suggest mutant genes exist that can functionally substitute for MYC to maintain a neoplastic phenotype. We were unable to find specific chromosomal abnormalities that correlated with the propensity for a given tumor to relapse upon MYC inactivation. This may reflect that we did not analyze enough primary tumors to discern the specific abnormalities. Alternatively, the genetic alterations responsible for relapse may not be readily detectable by karyotypic analysis and instead may be a consequence of small genetic deletions or mutations. Finally, it is possible that the ability of a tumor to relapse reflects epigenetic features of a tumor, such as its particular differentiation state, which may influence either the consequences of MYC inactivation or the propensity of tumors cells to acquire novel genomic aberrations. Our observations that all relapsed tumors exhibited additional chromosomal abnormalities and that almost all exhibited novel clonal chromosomal translocations strongly suggest that tumors relapse through a genetic mechanism. The most common abnormality we observed in relapsed tumors was a nonbalanced translocation involving Chr 3. The translocating partner and breakpoint varied among different tumors, suggesting that more than one gene product was involved. Nonreciprocal translocations are considered a hallmark of human cancer25 but are rarely found in human lymphomas and leukemias. Telomeres are generally protected from chromosome fusions.26 This could indicate that in our model system, the telomere of Chr 3 might have been shortened and was unable to protect the end from fusing to another chromosome. The distal part of Chr 3 is homologous to human chromosome 1p22-p31. According to the chromosomal abnormality database,27 this chromosomal region has been reported to undergo allelic loss in different types of tumors, and it also shows balanced chromosomal abnormalities in lymphomas and leukemias. Based on these observations, we propose the existence of an important tumor progression locus in the distal region of Chr 3, which presumably becomes involved in tumor development by promiscuous chromosomal translocations. These translocations may result in the disruption of the healthy function of a gene product, which can at least partially phenocopy the effects of MYC overexpression. The activation of oncogenes and the loss of function of tumor-suppressor genes are known to cooperate with MYC in tumorigenesis or to enhance tumor formation. These genetic events would be potential candidates for the mechanism by which tumors exhibit the propensity to relapse or to acquire the ability to become independent of MYC overexpression.2,4 Specifically, the loss of p19ARF and p53 function are known to cooperate with MYC in the initial steps of tumorigenesis.11 We examined whether any of the genes known to cooperate with MYC are located on the chromosomes that were altered. The mouse p19ARF locus is located on MMU4. This chromosome was frequently involved in a Robertsonian translocation (Rob).4 This kind of translocation is not thought to cause any genetic alterations because the chromosomal material remains intact. In addition, the p19ARF gene is situated in the middle of the chromosome and is therefore not likely to be altered. Trp53 (p53) is located on Chr 11. In 3 of the relapsed tumors, 2 of which were derived from the same primary tumor, this chromosome was involved in a structural rearrangement that resembled an interstitial C-band together with an amplification of part of the chromosome. Because p53 is located on the middle of the chromosome, it should not be affected by this rearrangement. Thus, it does not appear that p19ARF or p53 function is disrupted through gross chromosomal rearrangements or deletions. We presume that these functions are likely disrupted through other genetic or epigenetic mechanisms, as has been frequently observed in MYC-induced tumors. We are investigating whether p53 function is disrupted in our tumors. Some of the chromosomal abnormalities are proximal to oncogenes known to cooperate with MYC. In 2 of the relapsed tumors, the entire Chr 18 had translocated to part of Chr 1. The oncogene Bcl-2 is located on the middle of Chr 1 at 59.8 cM. Overexpression of Bcl-2 blocks many cell death pathways, and Bcl-2 is known to cooperate with Myc to promote tumorigenesis.7 The position of Bcl-2 corresponds to band D. The breakpoint of the translocation occurred at band D, which might be close to the location of Bcl-2. Because of the imprecision of cytogenetic position, we cannot exclude that Bcl-2 was altered in these 2 tumors and that this alteration contributed to tumorigenesis. However, we failed to observe the increased expression of Bcl-2 by Western blot analysis, making it unlikely that this gene product has been activated (data not shown). In 1 primary and 2 relapsed tumors, there was a translocation involving the fusion of Chr 17 to part of Chr 3 [t(3;17)]. The oncogenes Pim-1 and Pim-2, which have been described earlier to cooperate with Myc,9,10 are both located on Chr 17. None of the Pim genes are located near the fusion point, which indicates that their expression is not altered by the translocation in these tumors. Thus, we do not have evidence that a particular oncogene is associated with the chromosomal aberrations we observed. We considered that because hematopoietic tumors frequently exhibit the activation of oncogenes through their translocation to immunoglobulin or T-cell receptor loci, the chromosomal deletions or translocations we observed could be associated with one of these loci. However, none of the chromosomes, or even regions of chromosomes, in which immunoglobulin or T-cell receptor genes are located were significantly altered or involved in any of the observed translocations. We conclude that the chromosomal translocations observed in the relapsed tumors are likely to be associated with the activation or inactivation of previously uncharacterized genes. We have shown that tumorigenesis is reversible with the inactivation of a single oncogene, even in genetically highly complex and genomically unstable tumors. These observations make it more likely that the targeted inactivation of oncogenes may be effective in the treatment of human cancers. We demonstrate that the propensity for a given tumor to relapse appears to be an intrinsic property of each tumor. Moreover, the ability of a cancer to become independent of an oncogene was found to be associated with the acquisition of specific chromosomal translocations. Because MYC overexpression can cause genomic destabilization, we speculate that MYC may directly contribute to the generation of these chromosomal translocations. Indeed, we recently found that MYC overexpression may contribute to genomic instability by disrupting double-strand DNA break repair (A.K. et al, manuscript submitted). Thus, although MYC inactivation induces tumor regression, the ability of MYC to cause genomic destabilization may be responsible for the ability of some tumors cells to acquire the compensatory genetic lesions required to avert dependence on MYC for their neoplastic properties. We hope to be able to define the specific genetic contexts in which the inactivation of MYC is sufficient to induce sustained tumor regression, the mechanisms by which MYC facilitates tumor relapse, and the genetic changes responsible for the ability of tumors to escape dependence on MYC.
We thank the members of the Felsher laboratory and Drs Michael Cleary and Joseph Lipsick for helpful suggestions.
Submitted October 11, 2002; accepted November 18, 2002.
Prepublished online as Blood First Edition Paper, November 27, 2002; DOI 10.1182/blood-2002-10-3091.
Supported by National Cancer Institute grants K08-CA75967-01 and R01-CA89305-01, the Lymphoma Research Foundation of America, the Leukemia Research Foundation, the V Foundation, the Esther Ehrman Lazard Faculty Scholar, and the Elsa Pardee Foundation (D.W.F).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Dean Felsher, Division of Oncology, CCSR 1105, Stanford University, 269 Campus Dr, Stanford, CA 94305-5151; e-mail: dfelsher{at}stanford.edu.
1. Bishop JM. Molecular themes in oncogenesis. Cell. 1991;64:235-248[CrossRef][Medline] [Order article via Infotrieve]. 2. Grandori C, Cowley SM, James LP, Eisenman RN. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol. 2000;16:653-699[CrossRef][Medline] [Order article via Infotrieve].
3.
Hecht JL, Aster JC.
Molecular biology of Burkitt's lymphoma.
J Clin Oncol.
2000;18:3707-3721 4. Oster SK, Ho CS, Soucie EL, Penn LZ. The myc oncogene: MarvelouslY Complex. Adv Cancer Res. 2002;84:81-154[Medline] [Order article via Infotrieve]. 5. Boxer LM, Dang CV. Translocations involving c-myc and c-myc function. Oncogene. 2001;20:5595-5610[CrossRef][Medline] [Order article via Infotrieve].
6.
Land H, Chen AC, Morgenstern JP, Parada LF, Weinberg RA.
Behavior of myc and ras oncogenes in transformation of rat embryo fibroblasts.
Mol Cell Biol.
1986;6:1917-1925 7. Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature. 1988;335:440-442[CrossRef][Medline] [Order article via Infotrieve]. 8. Haupt Y, Bath ML, Harris AW, Adams JM. bmi-1 transgene induces lymphomas and collaborates with myc in tumorigenesis. Oncogene. 1993;8:3161-3164[Medline] [Order article via Infotrieve]. 9. van Lohuizen M, Verbeek S, Krimpenfort P, et al. Predisposition to lymphomagenesis in pim-1 transgenic mice: cooperation with c-myc and N-myc in murine leukemia virus-induced tumors. Cell. 1989;56:673-682[CrossRef][Medline] [Order article via Infotrieve]. 10. Allen JD, Verhoeven E, Domen J, van der Valk M, Berns A. Pim-2 transgene induces lymphoid tumors, exhibiting potent synergy with c-myc. Oncogene. 1997;15:1133-1141[CrossRef][Medline] [Order article via Infotrieve].
11.
Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL.
Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Genes Dev.
1999;13:2658-2669 12. Liyanage M, Coleman A, du Manoir S, et al. Multicolour spectral karyotyping of mouse chromosomes. Nat Genet. 1996;14:312-315[CrossRef][Medline] [Order article via Infotrieve].
13.
Rao PH, Cigudosa JC, Ning Y, et al.
Multicolor spectral karyotyping identifies new recurring breakpoints and translocations in multiple myeloma.
Blood.
1998;92:1743-1748 14. McCormack SJ, Weaver Z, Deming S, et al. Myc/p53 interactions in transgenic mouse mammary development, tumorigenesis and chromosomal instability. Oncogene. 1998;16:2755-2766[CrossRef][Medline] [Order article via Infotrieve]. 15. Coleman AE, Ried T, Janz S. Chromosomes 1 and 5 harbor plasmacytoma progressor genes in mice. Genes Chrom Cancer. 2000;29:170-174. 16. Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4:199-207[CrossRef][Medline] [Order article via Infotrieve]. 17. Chin L, Tam A, Pomerantz J, et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 1999;400:468-472[CrossRef][Medline] [Order article via Infotrieve].
18.
Fisher GH, Wellen SL, Klimstra D, et al.
Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes.
Genes Dev.
2001;15:3249-3262 19. Huettner CS, Zhang P, Van Etten RA, Tenen DG. Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat Genet. 2000;24:57-60[CrossRef][Medline] [Order article via Infotrieve].
20.
Jain M, Arvanitis C, Chu K, et al.
Sustained loss of a neoplastic phenotype by brief inactivation of MYC.
Science.
2002;297:102-104 21. Pelengaris S, Khan M, Evan GI. Suppression of Myc-induced apoptosis in beta cells exposes multiple oncogenic properties of Myc and triggers carcinogenic progression. Cell. 2002;109:321-334[CrossRef][Medline] [Order article via Infotrieve].
22.
Weinstein IB.
Addiction to oncogenes 23. Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell. 2002;1:289-298[CrossRef][Medline] [Order article via Infotrieve].
24.
Felsher DW, Bishop JM.
Transient excess of MYC activity can elicit genomic instability and tumorigenesis.
Proc Natl Acad Sci U S A.
1999;96:3940-3944 25. Artandi SE, DePinho RA. Mice without telomerase: what can they teach us about human cancer? Nat Med. 2000;6:852-855[CrossRef][Medline] [Order article via Infotrieve]. 26. Reddy KS, Murphy T. Fusion of 9 beta-satellite and telomere (TTAGGG)n sequences results in a jumping translocation. Human Genet. 2000;107:268-275[CrossRef][Medline] [Order article via Infotrieve]. 27. Mitelman F, Mertens F, Johansson B. A breakpoint map of recurrent chromosomal rearrangements in human neoplasia. Nat Genet. 1997;Spec No:417-474[CrossRef].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  S. J. Horton, V. Walf-Vorderwulbecke, S. J. Chatters, N. J. Sebire, J. de Boer, and O. Williams Acute myeloid leukemia induced by MLL-ENL is cured by oncogene ablation despite acquisition of complex genetic abnormalities Blood, May 14, 2009; 113(20): 4922 - 4929. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. B. Sampson, N. H. Rong, J. Han, Q. Yang, V. Aris, P. Soteropoulos, N. J. Petrelli, S. P. Dunn, and L. J. Krueger MicroRNA Let-7a Down-regulates MYC and Reverts MYC-Induced Growth in Burkitt Lymphoma Cells Cancer Res., October 15, 2007; 67(20): 9762 - 9770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Shachaf, O. D. Perez, S. Youssef, A. C. Fan, S. Elchuri, M. J. Goldstein, A. E. Shirer, O. Sharpe, J. Chen, D. J. Mitchell, et al. Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis Blood, October 1, 2007; 110(7): 2674 - 2684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-H. Wu, J. van Riggelen, A. Yetil, A. C. Fan, P. Bachireddy, and D. W. Felsher Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation PNAS, August 7, 2007; 104(32): 13028 - 13033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. W. Felsher Validating Oncogenes as Therapeutic Targets Using Conditional Transgenic Models Am. Assoc. Cancer Res. Educ. Book, April 14, 2007; 2007(1): 27 - 36. [Full Text] [PDF]
|
|
|
|
|
|
A. D. Slack, Z. Chen, A. D. Ludwig, J. Hicks, and J. M. Shohet MYCN-Directed Centrosome Amplification Requires MDM2-Mediated Suppression of p53 Activity in Neuroblastoma Cells Cancer Res., March 15, 2007; 67(6): 2448 - 2455. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Giuriato, S. Ryeom, A. C. Fan, P. Bachireddy, R. C. Lynch, M. J. Rioth, J. van Riggelen, A. M. Kopelman, E. Passegue, F. Tang, et al. Sustained regression of tumors upon MYC inactivation requires p53 or thrombospondin-1 to reverse the angiogenic switch PNAS, October 31, 2006; 103(44): 16266 - 16271. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ray, K. R. Atkuri, D. Deb-Basu, A. S. Adler, H. Y. Chang, L. A. Herzenberg, and D. W. Felsher MYC Can Induce DNA Breaks In vivo and In vitro Independent of Reactive Oxygen Species. Cancer Res., July 1, 2006; 66(13): 6598 - 6605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Beverly, D. W. Felsher, and A. J. Capobianco Suppression of p53 by Notch in Lymphomagenesis: Implications for Initiation and Regression Cancer Res., August 15, 2005; 65(16): 7159 - 7168. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Louis, B. J. Vermolen, Y. Garini, I. T. Young, A. Guffei, Z. Lichtensztejn, F. Kuttler, T. C. Y. Chuang, S. Moshir, V. Mougey, et al. c-Myc induces chromosomal rearrangements through telomere and chromosome remodeling in the interphase nucleus PNAS, July 5, 2005; 102(27): 9613 - 9618. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Yu, M. Dews, A. Park, J. W. Tobias, and A. Thomas-Tikhonenko Inactivation of Myc in Murine Two-Hit B lymphomas Causes Dormancy with Elevated Levels of Interleukin 10 Receptor and CD20: Implications for Adjuvant Therapies Cancer Res., June 15, 2005; 65(12): 5454 - 5461. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Shachaf and D. W. Felsher Tumor Dormancy and MYC Inactivation: Pushing Cancer to the Brink of Normalcy Cancer Res., June 1, 2005; 65(11): 4471 - 4474. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Rothermund, K. Rogulski, E. Fernandes, A. Whiting, J. Sedivy, L. Pu, and E. V. Prochownik C-Myc-Independent Restoration of Multiple Phenotypes by Two C-Myc Target Genes with Overlapping Functions Cancer Res., March 15, 2005; 65(6): 2097 - 2107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Hutchin, M. S.T. Kariapper, M. Grachtchouk, A. Wang, L. Wei, D. Cummings, J. Liu, L. E. Michael, A. Glick, and A. A. Dlugosz Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle Genes & Dev., January 15, 2005; 19(2): 214 - 223. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. Shin, T. N. Fredrickson, J. W. Hartley, T. Suzuki, K. Agaki, and H. C. Morse III High-Throughput Retroviral Tagging for Identification of Genes Involved in Initiation and Progression of Mouse Splenic Marginal Zone Lymphomas Cancer Res., July 1, 2004; 64(13): 4419 - 4427. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yang, C. H. Contag, D. Felsher, C. M. Shachaf, Y. Cao, L. A. Herzenberg, L. A. Herzenberg, and J. W. Tung The E47 transcription factor negatively regulates CD5 expression during thymocyte development PNAS, March 16, 2004; 101(11): 3898 - 3902. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Genetics, Göteborg University,
Sweden.
Top
Abstract
Introduction
). All the nontreated mice died within 2 weeks.
